185 related articles for article (PubMed ID: 36585165)
1. Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone.
Yoroidaka T; Yamashita T; Murata R; Yoshihara K; Yoshihara S; Ueda M; Nakao S; Matsue K; Takamatsu H
Anticancer Res; 2023 Jan; 43(1):157-165. PubMed ID: 36585165
[TBL] [Abstract][Full Text] [Related]
2. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Derman BA; Kansagra A; Zonder J; Stefka AT; Grinblatt DL; Anderson LD; Gurbuxani S; Narula S; Rayani S; Major A; Kin A; Jiang K; Karrison T; Jasielec J; Jakubowiak AJ
JAMA Oncol; 2022 Sep; 8(9):1278-1286. PubMed ID: 35862034
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Costa LJ; Chhabra S; Medvedova E; Dholaria BR; Schmidt TM; Godby KN; Silbermann R; Dhakal B; Bal S; Giri S; D'Souza A; Hall AC; Hardwick P; Omel J; Cornell RF; Hari P; Callander NS
Lancet Haematol; 2023 Nov; 10(11):e890-e901. PubMed ID: 37776872
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
Lee JH; Park Y; Kang KW; Lee JJ; Lee HS; Eom HS; Do YR; Kim JS; Yoon SS; Shin DY; Koh Y; Kim KH; Lee WS; Jo JC; Lee YJ; Lee JY; Kim DS; Shim H; Chang MH; Kim SH; Min CK;
Ann Hematol; 2021 Aug; 100(8):2051-2059. PubMed ID: 33447888
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Costa LJ; Chhabra S; Medvedova E; Dholaria BR; Schmidt TM; Godby KN; Silbermann R; Dhakal B; Bal S; Giri S; D'Souza A; Hall A; Hardwick P; Omel J; Cornell RF; Hari P; Callander NS
J Clin Oncol; 2022 Sep; 40(25):2901-2912. PubMed ID: 34898239
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Jasielec JK; Kubicki T; Raje N; Vij R; Reece D; Berdeja J; Derman BA; Rosenbaum CA; Richardson P; Gurbuxani S; Major S; Wolfe B; Stefka AT; Stephens L; Tinari KM; Hycner T; Rojek AE; Dytfeld D; Griffith KA; Zimmerman TM; Jakubowiak AJ
Blood; 2020 Nov; 136(22):2513-2523. PubMed ID: 32735641
[TBL] [Abstract][Full Text] [Related]
8. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
9. A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.
Bhutani M; Foureau DM; Robinson M; Guo F; Fesenkova K; Atrash S; Paul B; Varga C; Friend R; Pineda-Roman M; Rigby K; Symanowski JT; Norek S; Tucker MR; Druhan LJ; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):535-544.e1. PubMed ID: 37127471
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
11. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Rocchi S; Tacchetti P; Pantani L; Mancuso K; Rizzello I; di Giovanni Bezzi C; Scalese M; Dozza L; Marzocchi G; Martello M; Barilà G; Antonioli E; Staderini M; Buda G; Petrini M; Cea M; Quaresima M; Furlan A; Bonalumi A; Cavo M; Zamagni E
Hematol Oncol; 2021 Feb; 39(1):41-50. PubMed ID: 33085797
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.
Tageja N; Korde N; Kazandjian D; Panch S; Manasanch E; Bhutani M; Kwok M; Mailankody S; Yuan C; Stetler-Stevenson M; Leitman SF; Sportes C; Landgren O
Bone Marrow Transplant; 2018 Nov; 53(11):1445-1449. PubMed ID: 29728700
[TBL] [Abstract][Full Text] [Related]
13. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Siegel DS; Dimopoulos MA; Ludwig H; Facon T; Goldschmidt H; Jakubowiak A; San-Miguel J; Obreja M; Blaedel J; Stewart AK
J Clin Oncol; 2018 Mar; 36(8):728-734. PubMed ID: 29341834
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
15. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.
Dimopoulos M; Wang M; Maisnar V; Minarik J; Bensinger W; Mateos MV; Obreja M; Blaedel J; Moreau P
J Hematol Oncol; 2018 Apr; 11(1):49. PubMed ID: 29615082
[TBL] [Abstract][Full Text] [Related]
16. [Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience].
Zherebtsova VA; Vorobyev VI; Gemdzhian EG; Ulyanova MA; Chernikov MV; Ivanova VL; Vinogradova OY; Ptushkin VV
Ter Arkh; 2021 Jul; 93(7):785-792. PubMed ID: 36286729
[TBL] [Abstract][Full Text] [Related]
17. KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients.
Palmieri S; Rocco S; Vitagliano O; Catalano L; Cerchione C; Vincelli ID; Scopelliti A; Gentile M; Farina G; Barone M; Gagliardi A; Esposito D; Arcamone M; Amico V; Fontana R; Sementa A; Sica A; Svanera G; Pane F; Ferrara F
Ann Hematol; 2020 Dec; 99(12):2903-2909. PubMed ID: 32583088
[TBL] [Abstract][Full Text] [Related]
18. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
[TBL] [Abstract][Full Text] [Related]
19. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
Leypoldt LB; Tichy D; Besemer B; Hänel M; Raab MS; Mann C; Munder M; Reinhardt HC; Nogai A; Görner M; Ko YD; de Wit M; Salwender H; Scheid C; Graeven U; Peceny R; Staib P; Dieing A; Einsele H; Jauch A; Hundemer M; Zago M; Požek E; Benner A; Bokemeyer C; Goldschmidt H; Weisel KC
J Clin Oncol; 2024 Jan; 42(1):26-37. PubMed ID: 37753960
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A
Blood Cancer J; 2017 Apr; 7(4):e554. PubMed ID: 28430175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
